Effect of different induction therapies on the clinical outcomes of ABO-incompatible living donor kidney transplantation recipients
10.3760/cma.j.issn.0254-1785.2019.02.004
- VernacularTitle:不同免疫诱导方案对ABO血型不相容亲属活体肾移植受者临床结局的影响
- Author:
Wenhua LEI
1
;
Shuaihui LIU
;
Jingyi ZHOU
;
Jia SHEN
;
Wenqin XIE
;
Xi YAO
;
Er Meng' CEN
;
Jianghua CHEN
;
Hongfeng HUANG
Author Information
1. 浙江大学医学院附属第一医院肾脏病中心
- Keywords:
Kidney transplantation;
ABO blood group;
Incompatible;
Living donor;
Rabbit antithymocyte globulin;
Basiliximab
- From:
Chinese Journal of Organ Transplantation
2019;40(2):78-82
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the clinical outcomes of low-dose rabbit antithymocyte globulin (rATG ) vs basiliximab as induction therapy in recipients of ABO-incompatible kidney transplantation (ABOi-KT) .Methods Retrospective analysis was conducted for e the clinical data of 40 ABOi-KT recipients between March 2017 and March 2019 .17 recipients of them received induction therapy with basiliximab (basiliximab group) while another 23 recipients received low-dose rATG (rATG group ,rATG 25 mg/d × 3 d) .During a median follow-up period of 282 days , the data of serum creatinine and eGFR at 1 week and 1 month ,graft survival rate and complication rate of two groups were compared .Results No significant difference existed in age ,gender ,dialytic modality/ duration , blood groups of recipients , HLA mis-match , blood group antibody titers , dose of rituximab ,blood groups of donors or donor age ( P > 0 .05 ) . The times of double filtration plasmapheresis in Basiliximab group were more (P< 0 .05) .No significant difference existed in serum creatinine and eGFR at 1 week or 1 month ( P > 0 .05 ) . No significant difference existed in graft survival rate . No significant difference existed in rate of acute rejection ,parvovirus B19 infection , urinary tract infection or hematoma .Conclusions Low-dose of rATG is as effective as basiliximab for ABOi-KT recipients .And rATG does not increase the rate of infection .
